- Home
- GROY vs GOSS Comparison
GROY vs GOSS Comparison
Compare GROY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- GOSS
- Stock Information
- Founded
- GROY 2020
- GOSS 2015
- Country
- GROY Canada
- GOSS United States
- Employees
- GROY N/A
- GOSS N/A
- Industry
- GROY
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- GOSS Health Care
- Exchange
- GROY Nasdaq
- GOSS Nasdaq
- Market Cap
- GROY 618.0M
- GOSS 586.6M
- IPO Year
- GROY 2021
- GOSS 2019
- Fundamental
- Price
- GROY $3.65
- GOSS $2.99
- Analyst Decision
- GROY Strong Buy
- GOSS Strong Buy
- Analyst Count
- GROY 5
- GOSS 6
- Target Price
- GROY $4.86
- GOSS $8.60
- AVG Volume (30 Days)
- GROY 2.7M
- GOSS 4.6M
- Earning Date
- GROY 11-03-2025
- GOSS 11-06-2025
- Dividend Yield
- GROY N/A
- GOSS N/A
- EPS Growth
- GROY N/A
- GOSS N/A
- EPS
- GROY N/A
- GOSS N/A
- Revenue
- GROY $12,376,000.00
- GOSS $40,237,000.00
- Revenue This Year
- GROY $82.74
- GOSS N/A
- Revenue Next Year
- GROY $51.73
- GOSS $30.65
- P/E Ratio
- GROY N/A
- GOSS N/A
- Revenue Growth
- GROY 90.37
- GOSS N/A
- 52 Week Low
- GROY $1.16
- GOSS $0.66
- 52 Week High
- GROY $4.04
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- GROY 58.55
- GOSS 59.87
- Support Level
- GROY $3.55
- GOSS $2.61
- Resistance Level
- GROY $3.87
- GOSS $3.60
- Average True Range (ATR)
- GROY 0.20
- GOSS 0.30
- MACD
- GROY -0.03
- GOSS 0.02
- Stochastic Oscillator
- GROY 50.00
- GOSS 50.20
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.